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Background: We sought to determine temporal trends in the receipt of prostatectomy or locoregional
radiation to the prostate for patients with metastatic prostate cancer and to identify predictors of receipt
of local treatment.
Methods: We identified 39,976 patients with metastatic prostate cancer diagnosed in 2004e2012 using
the National Cancer Database (NCDB). We used logistic multivariable regression to determine trends in
the receipt of prostate and/or pelvic radiation or radical prostatectomy after adjusting for demographic
and clinical factors.
Results: Patients with metastatic disease were less likely to receive locoregional treatment over time
[7.88% in 2004 vs. 5.53% in 2012, adjusted odds ratio (AOR)¼ 0.97 per year, 95% confidence interval (CI)¼
0.95e0.98; P< 0.001]. Cofactors associated with decreased likelihood for locoregional treatment
included older age (AOR¼ 0.96 per year, 95% CI¼ 0.96e0.96, P< 0.001) and increased comorbidity level
(1 comorbidity: AOR¼ 0.82, 95% CI¼ 0.73e0.93, P¼ 0.001; two or more comorbidities: AOR¼ 0.49, 95%
CI¼ 0.39e0.61, P< 0.001). Decreasing utilization of both radiation and surgery of the primary site
contributed to this trend. More specifically, patients with metastatic disease were less likely to receive
radiation to the prostate and/or pelvis over time (5.9% in 2004 vs. 4.2% in 2012, AOR¼ 0.97 per year, 95%
CI¼ 0.95e0.99, P< 0.001). Similarly, there was a trend toward decreased use of radical prostatectomy
(2.17% in 2004 compared to 1.31% in 2012, AOR¼ 0.96 per year, 95% CI 0.93e0.99, P¼ 0.01).
Conclusion: Despite recent evidence of the possible benefit for locoregional treatment of prostate
cancer in the setting of metastatic disease, rates of prostate radiation and radical prostatectomy among
this population have actually declined over the 8-year period between 2004 and 2012, suggesting slow
adoption of this novel treatment paradigm.
© 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer remains the second most frequently diagnosed
cancer in men and the leading cause of cancer death after lung
cancer.1 With the advent of improved awareness and screening
programs, more cases are diagnosed at the early stages of prostate
cancer. Still, <5% of patients will present with metastasis at diag-
nosis,2 and up to 40% of patients will experience recurrence ofwas presented at the ASTRO
n Oncology, Brigham and
5, USA.
uyen).
te Society, Published by Elsevierdisease after conventional radical therapy.3 Although the 5-year
cause-specific survival rate for men who present without metas-
tasis is nearly 100%, patients who present with metastasis have
only 28% survival expectancy.4 Appropriate treatment for this
group of patients therefore remains an active area of interest.
Current guidelines recommend immediate or deferred hormone
therapy [androgen deprivation therapy (ADT)] as palliative therapy
for metastatic prostate cancer.5 This treatment modality offers
improvement of disease-related symptoms, delayed tumor pro-
gression, and increased survival.3 Recent studies suggest that the
use of local treatment of the primary tumormay improve outcomes
for metastatic patients.6e11 Similar work in breast cancer,12 colon
cancer,13 and ovarian cancer14 has suggested a survival benefit from
local surgery or radiation.Korea LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient demographics.
No LTx (n¼ 37,224) LTx (n¼ 2,752) P
Median age (IQR) 72 (63e81) 66 (59e74) 0.0001
Race (%) 0.001
White 28,106 (75.5) 2,156 (78.3)
African American 7,530 (20.2) 483 (17.6)
Other 701 (1.9) 51 (1.9)
Unknown 887 (2.4) 62 (2.3)
Education levela) <0.001
Bottom quartile 7,610 (20.4) 488 (17.7)
Second quartile 8,583 (23.1) 616 (22.4)
Third quartile 8,119 (21.8) 600 (21.8)
Top quartile 11,348 (30.5) 945 (34.3)
Unknown 1,564 (4.2) 103 (3.7)
Income levelb)
Bottom quartile 6,345 (17.0) 393 (14.3)
Second quartile 6,791 (18.2) 463 (16.8)
Third quartile 10,032 (27.0) 730 (26.5)
Top quartile 12,497 (33.6) 1,064 (38.7)
Unknown 1,559 (4.2) 102 (3.7)
Comorbidities
(CharlsoneDeyo Score)
<0.001
None 28,476 (76.5) 2,316 (84.2)
One 5,973 (16.0) 346 (12.6)
Two or more 2,775 (7.5) 90 (3.3)
PSA, ng/mL (%) <0.001
<10 3,942 (10.6) 876 (31.8)
10e19 3,844 (10.3) 456 (16.6)
20e30 2,355 (6.3) 200 (7.3)
>30 26,535 (71.3) 1,181 (42.9)
Unknown 548 (1.5) 39 (1.4)
Treatment center type <0.001
Nonacademic 24,603 (66.1) 1,688 (61.3)
Academic 12,596 (33.8) 1,061 (38.6)
Unknown 25 (0.1) 3 (0.1)
IQR, interquartile range; LTx, locoregional treatment; PSA, prostate-specific
antigen.
a) Education level is determined by proportion of residents in the patient's area
code who have achieved a minimum high school degree with the bottom quartile
ranking as areas with the lowest degree rates.
b) Income level is determined by average income of patients provided by zip
code.
Prostate Int 5 (2017) 89e9490Although data supporting local treatment of metastatic prostate
cancer have accumulated in recent years, the retrospective nature
of these studies has limited a more widespread adoption of the
treatment paradigm. We sought to assess how trends in the
treatment of metastatic prostate cancer have evolved in light of the
shifting evidence for and against local treatment. Reflecting on
current clinical practice patterns may inform future directions for
study in these challenging patients.
2. Materials and methods
2.1. Data acquisition
Patient information was obtained from the National Cancer
Database (NCDB) after approval from the DanaeFarber/Harvard
Cancer Center Institutional Review Board. The NCDB is a national
oncology database overseen by the Commission on Cancer and the
American Cancer Society. Collectively, the database encompasses
70% of all newly diagnosed cases of cancer in the United States. For
our purposes, patients with a diagnosis of prostate cancer were
selected (n¼ 1,802,596). We used a subset of patients with meta-
static disease at the time of diagnosis based on the variable coded
by the Collaborative Stage Data Collection System. The study was
limited to patients diagnosed after 2004, when the variable was
first introduced to the database (n¼ 39,976). Patients for whom
treatment data were unavailable were excluded.
2.2. Statistical analysis
Patient informationwas entered into STATA software (StataCorp
LP, College Station, Texas, version 14.1) for data analysis. De-
mographic informationwas calculated according to coded variables
in the NCDB database. Comparison of categorical variables was
made using the chi-square test, whereas continuous variables were
compared with Student t test. Logistic regression was performed in
STATA for the treatment modalities of interest using year of diag-
nosis as a covariate and controlling for potential confounding fac-
tors such as age, race, income, education level, and comorbidity
level (based on CharlsoneDeyo Score).We used a two-sided P value
of < 0.05 as the criterion for statistical significance.
3. Results
3.1. Patient demographics
Based on review, 39,976 patients with metastatic prostate can-
cer diagnosed from 2004 to 2012 were identified. Patients were
classified as those receiving definitive locoregional treatment
(surgery or radiation of the primary tumor, n¼ 2,752) or no
locoregional treatment (n¼ 37,224). From surgical cases, we did not
count as definitive any patients who received only local destruction
of tumor or local excision, or subtotal prostatectomy, or unspecified
surgical procedures. Population characteristics are presented in
Table 1 comparing no locoregional treatment to patients receiving
locoregional treatment. Notable differences included increased age,
higher rates of comorbidities, and higher rates of elevated prostate-
specific antigen (PSA) among patients who did not receive locore-
gional therapy. Patients receiving locoregional therapy were more
likely to have been treated at an academic institution.
3.2. Trends in time show decreasing utilization of locoregional
treatment
Multivariable logistic regression showed that from 2004 to
2012, patients were less likely to receive locoregional treatment formetastatic prostate cancer [7.88% in 2004 vs. 5.53% in 2012,
adjusted odds ratio (AOR)¼ 0.97 per year, 95% confidence interval
(CI)¼ 0.95e0.98, P< 0.001] (Fig. 1). Cofactors associated with
decreased likelihood for locoregional treatment included older age
(AOR¼ 0.96, 95% CI¼ 0.96e0.96, P< 0.001) and increased comor-
bidity level (1 comorbidity: AOR¼ 0.82, 95% CI¼ 0.73e0.93,
P¼ 0.001; 2 or more comorbidities: AOR¼ 0.49, 95%
CI¼ 0.39e0.61, P< 0.001). Patients in the top income quartile
assessed by zip code were found to be more likely to receive
locoregional treatment (AOR¼ 1.25 per year, 95% CI¼ 1.06e1.48,
P¼ 0.007). Race, education, and income level did not otherwise
predict receipt of locoregional treatment (Table 2).3.3. Trends in locoregional therapy are contributed to by decreased
use of both radiation and surgery
Trends in utilization of locoregional therapy were subdivided
into treatment with radiation to the prostate and/or pelvis or sur-
gery of the primary site for further analysis. Radiation therapy
included the use of external beam and brachytherapy or combined
modality treatment. Multivariable logistic regression again showed
that patients were less likely to receive locoregional radiation (5.9%
in 2004 to 4.2% in 2012, AOR¼ 0.97 per year, 95% CI¼ 0.95e0.99,
P< 0.001) (Table 3). Treatment with radiation was also stratified by
PSA (recorded as the highest PSA documented prior to diagnostic
biopsy) to see if trends were different in patients with low PSA as a
Fig. 1. Trends in locoregional therapy during study period of 2004e2012.
Table 2
Multivariate logistic regression of changes in locoregional therapy usage over time
stratified by covariates.
Covariate AOR 95% CI P
Age 0.96 0.96e0.96 <0.001
Race
White 1.13 0.86e1.48 0.376
Black 0.87 0.65e1.15 0.321
Education level
Bottom quartile Ref
Second quartile 1.06 0.92e1.21 0.425
Third quartile 1.06 0.91e1.23 0.431
Top quartile 1.16 0.99e1.36 0.073
Income level
Bottom quartile Ref
Second quartile 1.06 0.91e1.23 0.454
Third quartile 1.11 0.95e1.29 0.178
Top quartile 1.25 1.06e1.48 0.007
Comorbidities (CharlsoneDeyo Score)
None Ref
One 0.82 0.73e0.93 0.001
Two or more 0.49 0.39e0.61 <0.001
AOR, adjusted odds ratio; CI, confidence interval.
Table 3
Adjusted odds ratio of changes in treatment modalities over time.
Treatment type AOR 95% CI P
Locoregional 0.97 0.95e0.98 <0.001
M1a 0.97 0.93e1.01 0.15
M1b 0.96 0.94e0.98 <0.001
M1c 0.97 0.93e1.00 0.071
Radiation 0.97 0.95e0.99 <0.001
M1a 0.98 0.93e1.03 0.366
M1b 0.96 0.94e0.99 0.001
M1c 0.96 0.92e1.00 0.061
Surgery 0.96 0.93e0.99 0.01
M1a 0.95 0.88e1.02 0.18
M1b 0.97 0.93e1.01 0.125
M1c 0.99 0.92e1.06 0.725
Chemotherapy 0.99 0.97e1.00 0.131
M1a 0.99 0.94e1.05 0.819
M1b 0.99 0.97e1.01 0.373
M1c 1.02 0.99e1.05 0.239
ADT 1.05 1.04e1.06 <0.001
M1a 1.04 1.00e1.08 0.044
M1b 1.04 1.03e1.06 <0.001
M1c 1.03 1.01e1.05 0.007
ADT, androgen deprivation therapy; AOR, adjusted odds ratio; CI, confidence in-
terval; M1a, metastasis to distant lymph nodes; M1b, metastasis in bones± distant
lymph nodes; M1c, metastasis other than distant lymph nodes or bones.
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show any significant interaction between year of diagnosis and
PSA< 10.0 ng/mL (Pinteraction¼ 0.120). Finally, subgroup analysis
was performed for academic versus nonacademic centers. There
was no significant difference in the trends among patients treated
at academic versus nonacademic centers (Pinteraction¼ 0.839), as the
use of radiation decreased at both academic (6.5% in 2004 to 4.2% in
2012) and nonacademic (5.6% in 2004 to 4.2 in 2012) institutions.
Similarly, there was a trend toward decreased use of surgery of the
primary site for patients presenting with metastatic disease (2.17%
in 2004 compared to 1.31% in 2012, AOR¼ 0.96 per year, 95% CI
0.93e0.99, P¼ 0.01) (Fig. 2).
Finally, subgroup analysis of locoregional trends was performed
by stratifying over M stage. There was a decrease in the use of
locoregional treatment for M1b patients (metastasis in bone± -
distant lymph nodes), but the trend was not significant for M1a
(distant lymph nodes) or M1c (other distant metastasis± bone or
distant lymph nodes). In looking specifically at patients receiving
radiation, there was again a decrease in treatment for M1b patients
but not for M1a or M1c patients. No significant trends were found
among patients undergoing surgery (Table 3).3.4. Trends in use of systemic therapies differ over time
Use of systemic therapy including ADT and chemotherapy was
trended over time. Overall, there was no change in the use of
chemotherapy in newly diagnosed metastatic patients (AOR¼ 0.99,
95% CI 0.97e1.00, P¼ 0.13). By comparison, use of ADT in patients
with metastatic prostate cancer was higher than use of any
locoregional therapy. Logistic regression for use of ADT showed a
significant increase over time (70.2% in 2004 compared to 77.9% in
2012, AOR¼ 1.05 per year, 95% CI 1.04e1.06) (Fig. 2). Stratification
of systemic therapy by M stage (as above) showed a nonsignificant
increase in use of chemotherapy for M1c patients despite an overall
decrease chemotherapy use and decreases in the M1a and M1b
subgroups. The increase in use of ADTwas composed of increases in
treatment in all subgroups (M1aeM1c) (Table 3).4. Discussion
The objective of this study was to quantify changes in the use of
locoregional treatment for metastatic prostate cancer over time.
We found that the rate of locoregional treatment (radiation or
Fig. 2. Trends in treatments for metastatic prostate cancer show decreasing trends in locoregional treatment (A) radiation and (C) surgery, whereas systemic therapy shows no
significant trends in (C) chemotherapy and increasing trend in (D) hormone therapy.
Prostate Int 5 (2017) 89e9492surgery) given to the prostate decreased during our study period
(from 7.88% to 5.53% between 2004 and 2012), and that older age
and increased comorbidity on the CharlsoneDeyo score were pre-
dictors of decreased treatment. More specifically, subdivision of
locoregional treatment showed that the decreasing trend was
composed of decreases in both local radiation and surgery of the
primary site. Stratification by M stage showed a decrease in treat-
ment of M1b patients with locoregional therapies and a similar
decrease in use of radiation for M1b patients. Changes in treatment
of M1a and M1c patients along with use of surgery for oligometa-
static patients were not significant. Conversely, there was an
increasing trend in the use of ADT for newly diagnosed metastatic
patients.
This result was surprising because of the emerging data on the
potential value of locoregional treatment in node positive and
metastatic disease.6e11 For example, in a review of the SEER (Sur-
veillance, Epidemiology, and End Results)-Medicare database, Sat-
kunasivam et al15 showed that radical prostatectomy and intensity-
modulated radiation therapy (IMRT) were associated with
decreased risk of prostate cancer-specific mortality at 6 months
(52% reduction and 62% reduction, respectively) relative to no local
therapy for patients with metastatic prostate cancer. Additionally,
Culp et al3 showed that 5-year survival and disease-specific survival
were significantly higher after radical prostatectomy (67.4% and
75.8%, respectively) or brachytherapy (52.6% and 61.3%, respec-
tively) compared to no local treatment (22.5% and 48.7%, respec-
tively) among men with Stage IV disease.3 Most recently,
Loppenberg et al16 used NCDB data to demonstrate improved 3-
year overall mortality-free survival rates in metastatic prostate
cancer patients who were treated with local therapy compared tono local therapy (66% vs. 51%, respectively; P< 0.001). Parikh et al17
found that among NCDB patients, 5-year overall survival was
improved for patients who received local therapy compared to
those who did not (45.7% vs. 17.1%, P< 0.01), although only radical
prostatectomy and IMRTdbut not 2D/3D conformal radiation
therapydconferred overall survival benefit compared to no local
therapy. Notably, this study excluded patients who received
chemotherapy who were included here to inform comparisons
between local and systemic therapy use.17 Similarly, Rusthoven
et al18 found that among metastatic prostate cancer patients
treated with ADT, addition of prostate radiotherapy (RT) improved
overall survival on univariate (P< 0.001) and multivariate analysis
(hazard ratio¼ 0.624, 95% CI¼ 0.551e0.706, P< 0.001) adjusted for
age, year, race, comorbidity score, PSA level, Gleason score, T stage,
N stage, chemotherapy administration, treating facility, and insur-
ance status. Despite differences in inclusion criteria (notably,
exclusion of chemotherapy patients in Parikh et al's study17 and
limitation to ADT patients in Rusthoven et al's study18), our paper
aligns well with these NCDB studies in showing the decreasing
trend in use of local therapy despite the apparent benefit. Kaplan
et al19 discuss that treatment of the primary site may be of
importance in preventing further metastatic spread because of
factors secreted, in addition to oncogenic cells, that promote
growth in secondary sites. A supporting study showed that circu-
lating malignant cells had decreased metastatic potential after
treatment of the primary tumor.20 Specifically, in renal cell carci-
noma, two randomized trials comparing treatment of patients
presenting with metastatic cancer found that systemic therapy
combined with radical nephrectomy showed significant survival
benefit.21,22 These findings lend legitimacy to the theory that
Sinha et al / Metastatic prostate cancer 93locoregional treatment of the primary tumor may improve out-
comes for metastatic prostate cancer.
One possible explanation for the decreasing trend is that the
studies focusing exclusively on local therapy for metastatic disease
were published in recent years, and so there was no time for these
data to be reflected in practice patterns prior to 2012.3,4,15,16 How-
ever, it should be noted that there was some evidence suggesting
the value of definitive local therapy for node-positive disease prior
to 2012, and it is therefore still somewhat surprising that local
therapy continued in a downward trajectory from 2004 to 2012
rather than slightly increasing or being stable.7 Nevertheless, in the
absence of prospective, randomized data evaluating the use of local
therapy for metastatic disease, practice patterns have relied heavily
on previous recommendations. Several ongoing trials will inform
future changes in practice patterns. Notably, the STAMPEDE trial
(Systemic Therapy in Advancing or Metastatic Prostate Cancer:
Evaluation of Drug Efficacy, NCT00268476) and the HORRAD trial
(ISRCTN 06890529) will compare ADT alone to ADT with radiation.
PEACE1 (NCT01957436) will compare ADT± RT± abiraterone ace-
tate with prednisone± docetaxxel. Finally, study NCT01751438 will
compare systemic therapy combined with radiation or surgery to
systemic therapy alone. Changes in practice patterns in light of
these ongoing results ought to be compared to previous practice
patterns to better understand the changes in outcomes for patients
with metastatic prostate cancer.
Another possible explanation is that the years 2004 to 2012
were particularly exciting in terms of the development of new
systemic therapies for metastatic prostate cancer. Starting with
survival improvements from docetaxel in 2004 to the advent of
abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-
223 after 2008, the large number of new systemic therapies for
metastatic disease may have led physicians to use local therapy less
for metastatic disease. However, as none of these therapies is
permanently curative and as there is emerging retrospective data
on the potential value of definitive therapy in metastatic disease,
we may start to see this trend abate in future studies after 2012.
Additional randomized controlled trials may elucidate the utility of
radiation and surgery of the primary site. Accordingly, an additional
arm was added to the STAMPEDE trial, which will investigate the
role of RT in metastatic disease.23
Originally published in 1996, the National Comprehensive
Cancer Network guidelines recommend ADT as the primary treat-
ment modality for metastatic prostate cancer. Oligometastatic
disease, in particular, is treated with ADT alone per guidelines. Our
findings suggest that conformation to the National Comprehensive
Cancer Network guidelines was increasing in both academic and
nonacademic settings over this period, as the use of ADT for met-
astatic disease increased from 70.2% in 2004 compared to 77.9% in
2012.
In light of these emerging data, the decreasing trend in use of
locoregional treatment may change. The practice patterns illus-
trated in 2004e2012 may be contrasted to future trends as the
paradigm shifts. Changes in the outcomes of patients with meta-
static disease ought to be interpreted in light of the evolving
practice patterns illustrated here (Table 3). In addition, as the fre-
quency of screening for prostate cancer changes, more patientsmay
present with advanced disease. Understanding the treatment of
these complex patients will become increasingly important.
This study has certain limitations. As discussed, because our
dataset was limited to patients diagnosed between 2004 and 2012,
more recent trends could not be observed. In addition, owing to the
retrospective nature of the study, confounding factors may exist
that were not accounted for. Importantly, because detailed data
regarding metastatic number and sites for patients were not
available, this information could not be factored into treatmentconsideration. Finally, because of the data available in the NCDB, we
were unable to differentiate between trends in treatment for oli-
gometastatic versus widely metastatic disease. We attempted to
address this limitation using subgroup analysis based on PSA score,
but no differences were found.5. Conclusion
The use of definitive local treatment for metastatic prostate
cancer decreased from 2004 to 2012, possibly because of advances
in systemic therapy during this time. Given the recent accumu-
lating evidence on the value of local therapy in improving outcomes
for these patients, these trends may reverse in the future; however,
prospective randomized trials are needed to clarify the exact
benefit.Conflicts of interest
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